Clinical Scorecard: Neuroimaging Insights into Brain Changes Associated with Premenstrual Dysphoric Disorder: A Comprehensive Review
At a Glance
Category
Detail
Condition
Key Mechanisms
Alterations in top-down regulatory mechanisms and large-scale brain networks, including decreased activation in specific brain regions and increased activation in others. [Source needed]
Target Population
Care Setting
Key Highlights
PMDD affects approximately 1.6% of women of reproductive age.
First-line treatment typically involves SSRIs, with a 40% non-response rate.
Functional MRI reveals significant brain network alterations in PMDD patients.
PMDD is characterized by severe affective and cognitive symptoms leading to significant distress.
The disorder poses a higher suicidal risk compared to Premenstrual Syndrome (PMS). [Source needed]
Guideline-Based Recommendations
Diagnosis
Management
First-line treatment includes SSRIs; alternative options are limited. [Source needed]
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Women of reproductive age diagnosed with PMDD.
SSRIs are the first-line treatment, but many patients do not respond.
Clinical Best Practices
Utilize functional MRI to assess brain activity and connectivity in PMDD patients. [Source needed]
Differentiate PMDD from PMS based on symptom severity and impact on functioning.
